Literature DB >> 3675603

Pivampicillin-promoted excretion of pivaloylcarnitine in humans.

B Melegh1, J Kerner, L L Bieber.   

Abstract

Pivampicillin treatment of seven children (five boys and two girls) for 7 days significantly reduced the amounts of total acid-soluble carnitine, free carnitine, and long-chain acylcarnitines and increased the amounts of acid-soluble acylcarnitine in plasma. The fasting plasma levels of 3-hydroxybutyrate at the end of treatment were 15% of the control value. The levels of free fatty acids were decreased, whereas triglyceride levels were unaffected, indicating impaired fat metabolism. Daily urinary excretion of total carnitine was four to five times higher than controls after the first day of treatment, although the amounts of free carnitine and acetylcarnitine were decreased. The urinary acylcarnitines were isolated and characterized by gas chromatography/electron impact mass spectrometry and fast-atom bombardment mass spectrometry. Pivaloylcarnitine was the predominant urinary acylcarnitine; it represented greater than 96% of the increased excretion of total carnitine and 75-80% of the total conjugated pivalic acid. The renal clearance of acylcarnitines was comparable to that of creatinine, indicating no reabsorption of pivaloylcarnitine. These data suggest a detoxification function of carnitine for pivalic acid in humans.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3675603     DOI: 10.1016/0006-2952(87)90318-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  21 in total

1.  Pharmacokinetics and safety of ascending single doses of DZ-2640, a new oral carbapenem antibiotic, administered to healthy Japanese subjects.

Authors:  M Tanaka; K Kato; H Hakusui; Y Murakami; K Sato; Y Ito; K Kawamoto
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Application of a second-tier newborn screening assay for c5 isoforms.

Authors:  T Cloppenborg; N Janzen; Hj Wagner; U Steuerwald; M Peter; Am Das
Journal:  JIMD Rep       Date:  2013-11-06

3.  Involvement of recognition and interaction of carnitine transporter in the decrease of L-carnitine concentration induced by pivalic acid and valproic acid.

Authors:  Noboru Okamura; Shuichi Ohnishi; Hiroyuki Shimaoka; Ryo Norikura; Hiroshi Hasegawa
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

4.  In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin.

Authors:  M Tsuji; Y Ishii; A Ohno; S Miyazaki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

Review 5.  Acylcarnitines in intermediary metabolism.

Authors:  A C Sewell; H J Böhles
Journal:  Eur J Pediatr       Date:  1995-11       Impact factor: 3.183

Review 6.  Carnitine esters in metabolic disease.

Authors:  H Böhles; A Evangeliou; K Bervoets; I Eckert; A Sewell
Journal:  Eur J Pediatr       Date:  1994       Impact factor: 3.183

7.  Up-regulation of carnitine transporters helps maintain tissue carnitine levels in carnitine deficiency induced by pivalic acid.

Authors:  N Okudaira; M Fujigaki; T Nakayoshi; I Komiya; Y Sugiyama
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

8.  Plasma carnitine ester profile in adult celiac disease patients maintained on long-term gluten free diet.

Authors:  Judit Bene; Katalin Komlósi; Beáta Gasztonyi; Márk Juhász; Zsolt Tulassay; Béla Melegh
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

9.  Slow replenishment of carnitine deficiency after cessation of long-term treatment with pivaloyl-containing antibiotics.

Authors:  Q N Diep; T Bøhmer; J I Holme; A Torvik; O T Storrøsten; C W Loennecken; P Monstad; E Jellum
Journal:  Pharm World Sci       Date:  1993-10-15

10.  Transient reduction of human left ventricular mass in carnitine depletion induced by antibiotics containing pivalic acid.

Authors:  K Abrahamsson; M Mellander; B O Eriksson; E Holme; U Jodal; A Jönsson; S Lindstedt
Journal:  Br Heart J       Date:  1995-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.